PriceTargets.com logo

KalVista Pharmaceuticals - KALV Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $23.33
  • Forecasted Upside: 187.00%
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$8.13 As of 01/27/2023 01:00 AM ET
▼ -0.26 (-3.10%)

This chart shows the closing price for KALV by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New KalVista Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for KALV and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for KALV

Analyst Price Target is $23.33
▲ +187.00% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for KalVista Pharmaceuticals in the last 3 months. The average price target is $23.33, with a high forecast of $30.00 and a low forecast of $16.00. The average price target represents a 187.00% upside from the last price of $8.13.

This chart shows the closing price for KALV for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 4 investment analysts is to buy stock in KalVista Pharmaceuticals. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/7/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/5/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/3/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/4/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/2/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/31/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/30/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/29/2023

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/6/2022HC WainwrightLower TargetBuy$48.00 ➝ $16.00Low
10/5/2022SVB LeerinkLower TargetOutperform$45.00 ➝ $30.00Low
10/4/2022Needham & Company LLCLower TargetBuy$38.00 ➝ $24.00Low
7/8/2022SVB LeerinkLower TargetOutperform$51.00 ➝ $45.00N/A
7/8/2022Needham & Company LLCLower TargetBuy$42.00 ➝ $38.00N/A
3/11/2022HC WainwrightReiterated RatingBuy$48.00High
3/11/2022Needham & Company LLCLower TargetBuy$48.00 ➝ $42.00High
3/8/2022Roth CapitalReiterated RatingBuyMedium
12/12/2021SVB LeerinkReiterated RatingBuy$51.00High
12/10/2021Needham & Company LLCLower TargetBuy$50.00 ➝ $48.00Medium
9/12/2021SVB LeerinkReiterated RatingBuy$51.00Low
9/10/2021HC WainwrightReiterated RatingBuy$48.00Low
7/14/2021HC WainwrightReiterated RatingBuy$48.00Medium
3/16/2021SVB LeerinkReiterated RatingBuyLow
2/17/2021Roth CapitalBoost TargetBuy$30.00 ➝ $55.00Low
2/10/2021SVB LeerinkBoost TargetOutperform$39.00 ➝ $51.00Low
2/10/2021HC WainwrightBoost TargetPositive ➝ Buy$30.00 ➝ $48.00Low
2/9/2021Jefferies Financial GroupBoost TargetBuy$34.00 ➝ $61.00Low
2/9/2021Stifel NicolausBoost TargetPositive ➝ Buy$30.00 ➝ $54.00Low
1/26/2021Needham & Company LLCBoost TargetPositive ➝ Buy$25.00 ➝ $32.00Low
11/17/2020SVB LeerinkBoost TargetOutperform$28.00 ➝ $39.00Medium
7/2/2020HC WainwrightReiterated RatingBuyHigh
7/1/2020Needham & Company LLCReiterated RatingBuy$25.00High
6/15/2020HC WainwrightInitiated CoverageBuy$30.00 ➝ $30.00Low
4/1/2020SVB LeerinkReiterated RatingOutperformMedium
3/10/2020Needham & Company LLCReiterated RatingBuy$28.00High
12/10/2019Needham & Company LLCLower TargetBuy ➝ Buy$35.00 ➝ $28.00Medium
12/3/2019Needham & Company LLCReiterated RatingBuy$35.00High
10/25/2019Needham & Company LLCReiterated RatingBuy$35.00Medium
9/6/2019Roth CapitalSet TargetBuy$30.00High
7/29/2019SVB LeerinkInitiated CoverageOutperform ➝ Outperform$31.00Low
5/28/2019Roth CapitalReiterated RatingBuyHigh
5/15/2019Roth CapitalBoost TargetBuy$25.00 ➝ $30.00High
3/20/2019Needham & Company LLCInitiated CoverageBuy$35.00Low
12/14/2018Cantor FitzgeraldReiterated RatingBuy$32.00Low
11/12/2018Cantor FitzgeraldSet TargetBuy$32.00High
10/30/2018Jefferies Financial GroupInitiated CoverageBuy ➝ Buy$30.00Medium
10/15/2018Stifel NicolausInitiated CoverageBuyHigh
10/3/2018Cantor FitzgeraldSet TargetBuy$32.00Low
9/21/2018Cantor FitzgeraldInitiated CoverageOverweight ➝ Overweight$32.00High
7/10/2018Roth CapitalInitiated CoverageBuy$20.00Low
4/29/2018BTIG ResearchReiterated RatingBuyMedium
(Data available from 1/29/2018 forward)

News Sentiment Rating

0.33 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
7/3/2022
  • 0 very positive mentions
  • 3 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
8/2/2022
  • 1 very positive mentions
  • 1 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
9/1/2022
  • 4 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/1/2022
  • 4 very positive mentions
  • 10 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
Mentions as of
10/31/2022
  • 3 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/30/2022
  • 2 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/30/2022
  • 1 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/29/2023

Current Sentiment

  • 1 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

KalVista Pharmaceuticals logo
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, a plasma kallikrein inhibitor that completed a Phase II clinical trial for the treatment of DME; sebetralstat, which is initiation of the Phase 3 KONFIDENT trial as a potential oral, on-demand therapy for HAE attacks; KVD824, an oral product candidate for the treatment of HAE; and Factor XIIa, an oral inhibitor program which is in preclinical stage targets an enzyme in HAE. The company is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $8.13
Low: $7.94
High: $8.47

50 Day Range

MA: $6.18
Low: $5.04
High: $8.39

52 Week Range

Now: $8.13
Low: $4.12
High: $17.34

Volume

335,982 shs

Average Volume

395,376 shs

Market Capitalization

$200.16 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.07

Frequently Asked Questions

What sell-side analysts currently cover shares of KalVista Pharmaceuticals?

The following Wall Street sell-side analysts have issued research reports on KalVista Pharmaceuticals in the last year: HC Wainwright, Needham & Company LLC, Roth Capital, and SVB Leerink LLC.
View the latest analyst ratings for KALV.

What is the current price target for KalVista Pharmaceuticals?

3 Wall Street analysts have set twelve-month price targets for KalVista Pharmaceuticals in the last year. Their average twelve-month price target is $23.33, suggesting a possible upside of 187.0%. SVB Leerink LLC has the highest price target set, predicting KALV will reach $30.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $16.00 for KalVista Pharmaceuticals in the next year.
View the latest price targets for KALV.

What is the current consensus analyst rating for KalVista Pharmaceuticals?

KalVista Pharmaceuticals currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe KALV will outperform the market and that investors should add to their positions of KalVista Pharmaceuticals.
View the latest ratings for KALV.

What other companies compete with KalVista Pharmaceuticals?

Other companies that are similar to KalVista Pharmaceuticals include ProQR Therapeutics, AC Immune, Olema Pharmaceuticals, Verrica Pharmaceuticals and KemPharm. Learn More about companies similar to KalVista Pharmaceuticals.

How do I contact KalVista Pharmaceuticals' investor relations team?

KalVista Pharmaceuticals' physical mailing address is 55 Cambridge Parkway Suite 901E, CAMBRIDGE MA, 02142. The specialty pharmaceutical company's listed phone number is 857-999-0075 and its investor relations email address is [email protected] The official website for KalVista Pharmaceuticals is www.kalvista.com. Learn More about contacing KalVista Pharmaceuticals investor relations.